NEW YORK, Dec. 07, 2017 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI) ("BeyondSpring" or the "Company"), a late-stage clinical biopharmaceutical company focusing on the development of a pipeline of innovative immuno-oncology cancer therapies, announced today that the Company will host a key opinion leader (KOL) event on Thursday, Dec. 14, 2017, from 11:00 AM to 12:30 PM ET (New York Time).
Independent KOLs, along with members of BeyondSpring's management team, will host a series of presentations that provide an in-depth analysis of Plinabulin's position as a potential new standard of care in chemotherapy-induced neutropenia prevention due to its unique mechanism and the market's unmet need. The agenda will also feature a discussion of Plinabulin's neutropenia prevention effects seen in the ongoing Phase 3 non-small cell lung cancer (NSCLC) trial, as well as an overview of I/O combination clinical trials.
Featured speakers will include:
Dr. Douglas Blayney, Stanford University, former ASCO President and current Board Member of the NCCN Guidelines for neutropenia management. Dr. Blayney served as an investigator in clinical trials for Neupogen and Neulasta and is the principal investigator for both of BeyondSpring's ongoing registrational neutropenia trials.
Dr. Klaus Ley, La Jolla Institute for Allergy and Immunology. Dr. Ley has published more than 300 papers in peer-review journals and writes review articles on neutrophils for ScienceMagazine. Dr. Ley has received many awards, including The American Heart Association's 2016 Distinguished Scientist Award.
A live webcast of the event will be available online, which can be accessed through the Investor Relations section of BeyondSpring's website: http://ir.beyondspringpharma.com. Also, a replay of the webcast will be available on http://ir.beyondspringpharma.com following the event.
BeyondSpring is a global clinical stage biopharmaceutical company developing innovative immuno-oncology cancer therapies with a robust pipeline from internal development and from collaboration with University of Washington in de novo drug discovery using ubiquitination platform. BeyondSpring's lead asset, Plinabulin, is in a Phase 3 clinical trial as a direct anticancer agent in non-small cell lung cancer and a Phase 2/3 clinical program in the prevention of chemotherapy-induced neutropenia (CIN). BeyondSpring has a seasoned management team with many years of experience bringing drugs to market.
Studies on Plinabulin's method of action indicate that Plinabulin activates GEF-H1, a guanine nucleotide exchange factor. GEF-H1 activates downstream transduction pathways leading to the activation of the protein c-Jun. Activated c-Jun enters the nucleus of dendritic cells to upregulate immune-related genes, which contributes to the up-regulation of a series of genes leading to dendritic cell maturation, T-cell activation and other effects that prevent neutropenia. Plinabulin is given as a single IV infusion in each cycle, 30 minutes after completion of the chemotherapy, offering same day dosing, whereas G-CSF is given 24 hours after chemotherapy. In addition, the use of Plinabulin is not associated with bone pain, which is a frequent side effect with G-CSF.
Cautionary Note Regarding Forward-Looking Statements
This press release includes forward-looking statements that are not historical facts. Words such as "will," "expect," "anticipate," "plan," "believe," "design," "may," "future," "estimate," "predict," "objective," "goal," or variations thereof and variations of such words and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are based on BeyondSpring's current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors including, but not limited to, the anticipated amount needed to finance the company's future operations, unexpected results of clinical trials, delays or denial in regulatory approval process, our expectations regarding the potential safety, efficacy or clinical utility of our product candidates, or additional competition in the market. The forward-looking statements made herein speak only as of the date of this release and BeyondSpring undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.
Steve Silver / Jeffrey Goldberger
KCSA Strategic Communications
email@example.com / firstname.lastname@example.org
Caitlin Kasunich / Amy Singh
KCSA Strategic Communications
212.896.1241 / 212.896.1207
email@example.com / firstname.lastname@example.org
Source: BeyondSpring, Inc.